Vion's Cloretazine shows 50% response in elderly leukemia patients

By Elaine Rigoli

Tampa, Fla., June 5 - Vion Pharmaceuticals, Inc. said data from the recently completed multi-center phase 2 trial of CLI-033 in acute myelogenous leukemia showed a 50% overall response rate: 20 complete response and two patients with complete response with incomplete platelet recovery.

Of these remissions, 52% occurred in patients with intermediate cytogenetics and 47% in patients with unfavorable cytogenetics, according to a news release.

The data presented from this study was on a subset of 44 patients, with a median age of 76 years old, who had de novo acute myelogenous leukemia.

New Haven, Conn.-based Vion develops and commercializes cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.